{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:02:34Z","timestamp":1762542154293},"reference-count":26,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,1]]},"DOI":"10.1210\/jc.2013-1497","type":"journal-article","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T05:43:12Z","timestamp":1364535792000},"page":"1803-1807","source":"Crossref","is-referenced-by-count":44,"title":["Sustained Improvements in Plasma ACTH and Clinical Status in a Patient With Nelson's Syndrome Treated With Pasireotide LAR, a Multireceptor Somatostatin Analog"],"prefix":"10.1210","volume":"98","author":[{"given":"Laurence","family":"Katznelson","sequence":"first","affiliation":[{"name":"Stanford School of Medicine, Departments of Neurosurgery and Medicine, Stanford, California 94305-5821"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113290160400_B1","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3171\/foc.2007.23.3.7","article-title":"Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's syndrome","volume":"23","author":"Kelly","year":"2007","journal-title":"Neurosurg Focus"},{"key":"key\n\t\t\t\t2019041113290160400_B2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s002689910020","article-title":"Long-term results of total adrenalectomy for Cushing's disease","volume":"24","author":"Nagesser","year":"2000","journal-title":"World J Surg"},{"key":"key\n\t\t\t\t2019041113290160400_B3","first-page":"224","article-title":"Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients","volume":"52","author":"Kelly","year":"1983","journal-title":"Q J Med"},{"key":"key\n\t\t\t\t2019041113290160400_B4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing's syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113290160400_B5","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archpedi.1977.02120250035005","article-title":"Incidence of Nelson's syndrome after adrenalectomy for Cushing's disease in children: results of a nationwide survey","volume":"131","author":"Hopwood","year":"1977","journal-title":"Am J Dis Child"},{"key":"key\n\t\t\t\t2019041113290160400_B6","first-page":"1067","article-title":"Nelson's syndrome after Cushing's disease in childhood: a continuing problem","volume":"96","author":"Thomas","year":"1984","journal-title":"Surgery"},{"key":"key\n\t\t\t\t2019041113290160400_B7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/pgmj.72.843.53","article-title":"The effects of octreotide in a patient with Nelson's syndrome","volume":"72","author":"Kelestimur","year":"1996","journal-title":"Postgrad Med J"},{"key":"key\n\t\t\t\t2019041113290160400_B8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1530\/acta.0.1200760","article-title":"The effect of the long-acting somatostatin analogue SMS 201\u2013995 on ACTH secretion in Nelson's syndrome and Cushing's disease","volume":"120","author":"Lamberts","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113290160400_B9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03347703","article-title":"Long-term treatment of Nelson's syndrome by octreotide: a case report","volume":"17","author":"Petrini","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113290160400_B10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113290160400_B11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t2019041113290160400_B12","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113290160400_B13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113290160400_B14","first-page":"709","article-title":"ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome","volume":"26","author":"Kasperlik-Zaluska","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"key":"key\n\t\t\t\t2019041113290160400_B15","first-page":"300","article-title":"Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment","volume":"62","author":"Casulari","year":"2004","journal-title":"Horm Res"},{"key":"key\n\t\t\t\t2019041113290160400_B16","first-page":"514","article-title":"Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome","volume":"82","author":"Mercado-Asis","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113290160400_B17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11102-006-9290-4","article-title":"Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment","volume":"9","author":"Shraga-Slutzky","year":"2006","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113290160400_B18","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113290160400_B19","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019041113290160400_B20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113290160400_B21","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113290160400_B22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11102-012-0427-3","article-title":"Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review","volume":"15","author":"Shimon","year":"2012","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113290160400_B23","first-page":"502","article-title":"A conservative management is preferable in milder forms of pituitary tumor apoplexy","volume":"34","author":"Leyer","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113290160400_B24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1210\/jc.2006-1578","article-title":"Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets","volume":"92","author":"Singh","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113290160400_B25","article-title":"An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels [published online June 16, 2012]","author":"Shenouda","journal-title":"Am J Ther"},{"key":"key\n\t\t\t\t2019041113290160400_B26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","article-title":"Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide","volume":"39","author":"Reznik","year":"2013","journal-title":"Diabetes Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/5\/1803\/9044849\/jcem1803.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T14:27:40Z","timestamp":1562855260000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/5\/1803\/2536739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-1497","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,1]]}}}